| INTRODUCTION
Biochemical analysis of body fluids provides clinically useful information. Hemolysis, icterus, and lipemia (HIL) are the most common causes of blood sample inadequacy and interfere with the accurate measurement of various analytes. [1] [2] [3] [4] [5] Icterus interferes via bilirubin (BIL), in two ways: physical interference (light absorption) and chemical interference (with reagent components as H 2 O 2 ). 6 For every assay method, a cut-off value for Icterus (Icterus Index: I ict ) is established by the manufacturer and indicated on the insert sheet, 7 or recognized through laboratory experience. Therefore, a sample may be rejected if the I ict value exceeds this threshold. In the case of hemolysis (except if in vivo hemolysis), a new sample -without hemolysis -is required for accurate assay measure- The aim of this study is to determine which analyses are impacted when I ict increases and to propose a method of predicting, when possible, nominal interference-free analyte concentrations as a function of measured I ict .
| MATERIALS AND METHODS
This study was considered a quality assessment project and was therefore deemed exempt from ethics committee approval. It was conducted at La Conception Hospital, Biochemistry Laboratory, Marseille, France. To evaluate the effect of bilirubin on routine analytes, we analyzed the most common analytes reported by manufacturers to be affected by this interferent. We chose the most common, manufacturer-reported interferents and tested different levels of bilirubin. We provide a comprehensive report on the effect of this interference on the analytes listed in Table 1 .
We studied the effect of icterus interference on alanine amino- Two approaches were used to establish analytical performance goals:
The mean percentage deviation was compared to the Acceptable
Change Limit (ACL), according to ISO 5725-6. 10 The ACL for interpreting a measured difference is based on the analytical imprecision (CVa), using the formula ACL = 2.77 CVa.
2.
The second approach took into account acceptable imprecision, based on intra-individual biological variation. According to the College of American Pathologists recommendations, the imprecision of a method, for individual single and multipoint testing, should be equal or less than one-half of the average within-subject variation (CVb), and this should be the goal for short-term laboratory imprecision (≤0.5 CVb). The CVb of each analyte was taken from the listing of biological variation for 316 analytes by Ricos et al.
11
This database was most recently updated in 2014, but some analytes are still missing. 12 To monitor changes in an analyte from the same sample for the same individual, we combined the two approaches (analytical and intraindividual imprecisions) by estimating the square root of the sum of the squared analytical and biological imprecisions, defined as the total change limit (TCL):
The TCL is the square root of the sum of squared analytical reproducibility (CVa) (obtained from Roche Diagnostics QC) and biological imprecision (CVb) (found in "Ricos database" 11, 12 ):
Based on the results observed, a function between I ict and the variation in the analyte (in %) is estimated and optimized, depending on whether a linear or differing relationship to level is found.
We define X′ as the interference-free calculated value, X as value of the analyte at I ict , and X0 as the original value of the analyte (when I ict ≤1) corresponding to the unspiked pool. The analytes variation (in %) when I ict increase is D for the observed values and Z for the calculated values after correction.
Working from the I ict held in the laboratory, this relationship is used to estimate X′ from all the observed values and the I ict .
Based on results, the observed variation (D) in the analytes (in %) is D = 100 (X-X0)/X0. Whereas, D is also a function of I ict and is generally
X′ is calculated from I ict and X. After changing X0 for X′, the interference-free value is calculated from the relationship:
. Therefore, knowing X and I ict makes it possible to estimate X′.
The % of difference between X′ and X0 can be calculated. The goal is reached if less than 5% of Z (where Z = 100 (X′−X0)/X0)) gives a value below the TCL.
Data analysis was performed in Excel 2013 (Microsoft Inc.,
Redmond, WA, USA).
| RESULTS
As I ict was determinate by a simple measure of two wavelengths Between CHOLT and I ict , the relation is more complex (Figure 2 ).
For CHOLT, for the same decrease, 20% for example, I ict ranges from 20 to 50 depending on CHOLT level. In the same manner, for the same I ict , 30 for example, CHOLT decrease ranges from −12.8% to −24.3%.
Therefore, Figure 2g show the complexity of the relation, based on I ict but also on CHOLT level. In this case, Z is done only for CHOLT>4. In this condition, if I ict ≤40, the Z bias is less than 5%, when TCL is used as acceptable limit.
Relation between I ict and TBIL (μmol/L; see abbreviation in text). A linear relation is observed between I ict and TBIL. As I ict is always available (and not TBIL), a relation between I ict and the interference on the analytes should be studied 
| DISCUSSION AND CONCLUSION
While previous studies indicate that the chemical properties of bilirubin, whether conjugated (cBIL) or unconjugated (ucBIL), do not contribute to differences in interference, 5 Roche Diagnostics gives differing levels of interference for I ict with cBIL and ucBIL. Bilirubin may be present in some pathological circumstances, and therefore sera analysis could be impacted.
Our conclusion here is that Roche Diagnostics suggested icterus interference cut-off yield a bias ≥10%, except for GGT and TG (Table 1 ). For GGT, Roche Diagnostics indicates an I ict cut-off at 20, as no influence was observed in our study, which is in agreement with. 13 For TG, Roche Diagnostics suggested cut-off is half the value we observed. Roche Diagnostics consistently refers to Glick et al.
14 on HIL interference. In this publication, TG seems to increase when bilirubin is added. However, data show the opposite (Figure 2 ). In the latest available dataset, 7 Roche Diagnostics indicates that a decrease The protocol used here is both simple and efficient, requiring only the dilution of cBIL with physiological sera to spike the pool of sera.
We chose to spike the sera pool with cBIL because it is totally watersoluble. Previous studies have often used ucBIL. 5, 6, 20 However, in this case, ucBIL needs to be solubilized at high pH due to NaOH. The resulting pH increase could induce:
1. Spectral change in bilirubin, [21] [22] [23] transformation of bilirubin to biliverdin.
22,24
2. Possible change in analytical conditions for some analytes.
A possible explanation for Bilirubin's interference is the following.
CHOLT, CREA, HDLc, TG, and UA involve the same steps for determination in the analyzer. At the last step of the reaction, catalyzed by oxidase or peroxidase, the liberated hydrogen peroxide reacts with compounds to form a quinone imine chromogen (TRINDER reaction). The color intensity of the quinone imine chromogen formed is directly proportional to the analyte concentration in the reaction mixture.
However, Bilirubin interferes in oxidase/peroxidase-based test systems. 6, 19 Proportionally to its concentration, bilirubin reacts with In a strongly acidic solution, the absorption of conjugated bilirubin shifts to the UV wavelengths (340 nm). Therefore, bilirubin interferes F I G U R E 2 Relation between I ict and analytes. Observed variation before D (%) and after correction Z (%), allowable cut-off as ±TCL (%) and equations between I ict and D (%) are shown for PROT (A), AU (B), Phos (C), HDLc (D),TG (E), CREA (F), CHOLT (G) and FRUC (H in the determination of Phos via the phosphomolybdate method through its reducing effect, [25] [26] [27] because of the sulfuric medium. In an alkaline solution, the increase in absorption as a result of oxidation of bilirubin to biliverdin, which shows a broad band at about 650 nm, 28, 29 is the main cause of bilirubin interference 25 with FRUC and PROT.
Furthermore, to some extent, ucBIL in alkaline solution can react with copper to form Bil-Copper complex, which can contribute to PROT decrease.
30-33
This study presents some limitations. First, the results are based on assays using Roche Diagnostics analyzers for chemistry testing.
Further assays realized on other diagnostic analyzers might alter the conclusions. Based on Roche Diagnostics documentation, 7 others analytes in biochemistry that could be impacted by icterus are acid phosphatase, creatinine with Jaffé method, lithium and glucose (GOD PAP). None of these analytes are tested in our laboratory with these methods. Second, our results are validated on the studied range (table 1) , and extrapolations outside this range should not be made.
Third, results are validated for the TCL used in our laboratory. TCL values are calculated in such a way as to always obtain less than 5% of Z outside TCL after correction. Fourth, no overall solution appears for CHOLT when I ict increases. Finally, a totally enzymatic determination of creatinine plasmatic values would probably not involve the interference shown here.
In conclusion, this study shows that only some biochemical laboratory tests are impacted by icterus. For FRUC, HDLc, PROT, Phos, UA, TG, and CREA, we propose a method of estimating the interferencefree value. Only a partial solution was found for CHOLT. Based on I ict and the observed value, a corrected value can be reached, as is done for calcium using protein level. The suggestion to correct laboratory values that have interferences present is generally considered to be ill-advised this concept has been explored previously for hemolysis 34 and, in this case, the consensus is that correction may work for a data series, but would fail for individual patients. However, the methodology used here for Icterus, with significant data (n>300 values), the determination of the interference-free value which was under TCL, may be used for individual patients. The equation can easily be integrated into the MPL Roche Diagnostic analyzer®. I ict levels are based on analytical performance goals, and equations to recalculate interference-free values are also proposed. It appears that the impact of the arbitrary 10% threshold differs according to analyte (sodium vs LIP, for example). This suggests that cut-off levels should be assessed using the most appropriate methods as they evolve (CREA via enzymatic vs Jaffe, for example) and according to analyte. Finally, for the most important parameter, CREA, proper estimation is essential to establish the correct posology regarding GFR. With regard to icterus, CREA is generally underestimated, but our estimating method offers a good interference-free value suitable for clinicians.
